Rapport Therapeutics

📍 Boston, Massachusetts, United States🗓 Founded 2022👥 78 employees💰 Last funded Nov 2024
Biotechnology Research🌐 rapportrx.com
Website LinkedIn
Rapport Therapeutics aims to transform the treatment of neurological disorders through a precision medicine approach, precisely targeting disease-driving neurocircuits by leveraging receptor-associated proteins (RAPs). With this approach, Rapport can overcome the well-established limitations of today’s neuromedicines that act indiscriminately throughout the nervous system, resulting in suboptimal efficacy and burdensome side effects. Leading the hunt for precision medicines is a team with established track records of innovation in neuroscience and drug discovery. Rapport was conceptualized and created through a partnership between Third Rock Ventures and Johnson & Johnson Innovation-JJDC, Inc. (JJDC) and launched in March 2023. Rapport is based in San Diego, CA and Boston, MA. For more information, please visit www.rapportrx.com.
2
Total investors
2
Early stage
0
Mid stage
0
Late stage
2022
Founded

Investors

2 investors
All
Early stage
Mid stage
Late stage
Investor geography2 countries
United States
1
United Kingdom
1
Frequently asked questions
Who invested in Rapport Therapeutics?
Rapport Therapeutics has 2 investors on record on gritt.io, including 2 early-stage backers.
When did Rapport Therapeutics last raise funding?
The most recent investment in Rapport Therapeutics recorded on gritt.io was in November 2024.
When was Rapport Therapeutics founded?
Rapport Therapeutics was founded in 2022.
What industry is Rapport Therapeutics in?
Rapport Therapeutics operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is Rapport Therapeutics based?
Rapport Therapeutics is headquartered in Boston, Massachusetts, United States.